echemi logo
Product
  • Product
  • Supplier
  • Inquiry

    sii

    Get the latest sii news delivered straight to you. The information of sii is large on echemi.com.
    • Novavax and SII are authorized for emergency use of vaccines in India

      Time of Update: 2022-01-09
      The Novavax/SII vaccine has recently received emergency use authorization (EUA) in Indonesia and the Philippines, and has been included in the World Health Organization (WHO) Emergency Use List (EUL) . Novavax's vaccine has also received a conditional marketing authorization from the European Commission and is included in the WHO's Emergency Use List (EUL). com/2021-12-28-Novavax-and-Serum-Institute-of-India-Receive-Emergency-Use-Authorization-for-COVID-19-Vaccine-in-Indiahttps://ir. com/2021-12-28-Novavax-and-Serum-Institute-of-India-Receive-Emergency-Use-Authorization-for-COVID-19-Vaccine-in-India
    • Novavax and SII are authorized for emergency use of vaccines in Indonesia

      Time of Update: 2021-12-09
      (NASDAQ: NVAX), a biotechnology company dedicated to the development and commercialization of next-generation vaccines for severe infectious diseases, and Serum Institute of India Private Limited (SII), the world’s largest vaccine manufacturer, announced today that the National Agency for Medicines and Food Control of the Republic of Indonesia (Badan Peng was Obat dan Makanan (Badan POM)) has granted Novavax the use of Matrix-M™ adjuvant Emergency Use Authorization (EUA) for the recombinant nanoparticle protein new coronary pneumonia vaccine .
    • The Serum Institute of India (SII) will produce THE COVID-19 vaccine for AstraZeneca and Novavax.

      Time of Update: 2020-08-20
      similar ly, Novavax recently reported preliminary results from a Phase I/II study showing that its recombinant coronavirus vaccine candidate NVX-CoV2373 also triggered neutralizing antibodies in healthy adults, as well as cell immune responses from some of the participants.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.